Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Cost-effectiveness of etanercept treatment in early active rheumatoid arthritis followed by dose adjustment.

Kobelt G, Lekander I, Lang A, Raffeiner B, Botsios C, Geborek P.

Int J Technol Assess Health Care. 2011 Jul;27(3):193-200. doi: 10.1017/S0266462311000195. Epub 2011 Jul 8.

PMID:
21736857
2.

Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.

Woolacott N, Bravo Vergel Y, Hawkins N, Kainth A, Khadjesari Z, Misso K, Light K, Asseburg C, Palmer S, Claxton K, Bruce I, Sculpher M, Riemsma R.

Health Technol Assess. 2006 Sep;10(31):iii-iv, xiii-xvi, 1-239. Review.

3.

Treating to target with etanercept in rheumatoid arthritis: cost-effectiveness of dose reductions when remission is achieved.

Kobelt G.

Value Health. 2014 Jul;17(5):537-44. doi: 10.1016/j.jval.2014.04.005. Epub 2014 May 23.

4.

Cost utility of tumour necrosis factor-α inhibitors for rheumatoid arthritis: an application of Bayesian methods for evidence synthesis in a Markov model.

Nguyen CM, Bounthavong M, Mendes MA, Christopher ML, Tran JN, Kazerooni R, Morreale AP.

Pharmacoeconomics. 2012 Jul 1;30(7):575-93. doi: 10.2165/11594990-000000000-00000. Review. Erratum in: Pharmacoeconomics. 2012 Nov 1;30(11):1096.

PMID:
22640174
5.
7.

An economic approach to health care.

Homik JE, Suarez-Almazor M.

Best Pract Res Clin Rheumatol. 2004 Apr;18(2):203-18. Review.

PMID:
15121040
8.

A cost effectiveness analysis of treatment options for methotrexate-naive rheumatoid arthritis.

Choi HK, Seeger JD, Kuntz KM.

J Rheumatol. 2002 Jun;29(6):1156-65.

PMID:
12064828
9.

Treatment strategies aiming at remission in early rheumatoid arthritis patients: starting with methotrexate monotherapy is cost-effective.

Schipper LG, Kievit W, den Broeder AA, van der Laar MA, Adang EM, Fransen J, van Riel PL.

Rheumatology (Oxford). 2011 Jul;50(7):1320-30. doi: 10.1093/rheumatology/ker084. Epub 2011 Mar 2.

PMID:
21371999
10.

[Contribution of leflunomide to the cost effectiveness of sequential DMARD therapy of rheumatoid arthritis in Germany].

Schädlich PK, Zeidler H, Zink A, Gromnica-Ihle E, Schneider M, Straub C, Brecht JG, Huppertz E.

Z Rheumatol. 2004 Feb;63(1):59-75. German.

PMID:
14991279
11.

[Health-economic assessment of combination therapy for rheumatoid arthritis with methotrexat and etanercept based on the TEMPO Study].

Schulze-Koops H, Deeg M, Runge C, Volmer T, Brecht JG.

Z Rheumatol. 2009 Dec;68(10):836-41. doi: 10.1007/s00393-009-0506-7. German.

PMID:
19756664
12.

The cost-effectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis.

Bravo Vergel Y, Hawkins NS, Claxton K, Asseburg C, Palmer S, Woolacott N, Bruce IN, Sculpher MJ.

Rheumatology (Oxford). 2007 Nov;46(11):1729-35.

PMID:
17956918
13.

Economic evaluation of etanercept in the management of chronic plaque psoriasis.

Lloyd A, Reeves P, Conway P, Reynolds A, Baxter G.

Br J Dermatol. 2009 Feb;160(2):380-6. doi: 10.1111/j.1365-2133.2008.08863.x. Epub 2008 Sep 19.

PMID:
18808413
15.

Cost effectiveness of moderate to severe psoriasis therapy with etanercept and ustekinumab in the United States.

Villacorta R, Hay JW, Messali A.

Pharmacoeconomics. 2013 Sep;31(9):823-39. doi: 10.1007/s40273-013-0078-x.

PMID:
23975739
16.

Modeling and cost-effectiveness analysis of etanercept in adults with rheumatoid arthritis in Japan: a preliminary analysis.

Tanno M, Nakamura I, Ito K, Tanaka H, Ohta H, Kobayashi M, Tachihara A, Nagashima M, Yoshino S, Nakajima A.

Mod Rheumatol. 2006;16(2):77-84.

PMID:
16633926
17.

The cost-effectiveness of TNF-inhibitors for the treatment of rheumatoid arthritis in Swedish clinical practice.

Lekander I, Borgström F, Lysholm J, van Vollenhoven RF, Lindblad S, Geborek P, Kobelt G.

Eur J Health Econ. 2013 Dec;14(6):863-73. doi: 10.1007/s10198-012-0431-6. Epub 2012 Sep 19.

PMID:
22990378
18.

Modeling the cost-effectiveness of treatment of rheumatoid arthritis with rituximab using registry data from Southern Sweden.

Lindgren P, Geborek P, Kobelt G.

Int J Technol Assess Health Care. 2009 Apr;25(2):181-9. doi: 10.1017/S0266462309090230. Epub 2009 Mar 31.

PMID:
19331709
19.

Infliximab: a pharmacoeconomic review of its use in rheumatoid arthritis.

Lyseng-Williamson KA, Foster RH.

Pharmacoeconomics. 2004;22(2):107-32. Review.

PMID:
14731052
20.

Supplemental Content

Support Center